Abstract library

347 results for "Chotai de Lima".
#2806 Sarcopenia: Don't Judge a Book by It's Cover
Introduction: Sarcopenia is characterised by loss of muscle mass and function. We previously reported anthropometrical data for a range of NET diagnoses within 3 months of diagnosis. The majority of NET patients were overweight or obese, however reduced muscle function was observed in over half of patients regardless of BMI and other parameters.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Tara Whyand
#998 Intra and Interobserver Reproducibility of CT and MRI for Measurement of Liver Metastasis as a Basis of RECIST Evaluation in Patients with Neuroendocrine Tumors
Introduction: The reliability of RECIST evaluation in patients with NET has not yet been analyzed.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Julia Arfi Rouche
#1457 Small and Large Incidental Non-Hyperfunctiong Pancreatic Neuroendocrine Tumors: Spectrum of Magnetic Resonance Imaging Features
Introduction: The improvement of imaging techniques significantly increased the detection of small incidental non-hyperfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs). Most NF-PanNENs
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Riccardo De Robertis
#1870 Detection of Metastatic Insulinoma with 68Ga-NODAGA-Exendin-4 PET/CT in a Young Child – A Case Report
Introduction: Malignant insulinomas are extremely rare in children. Localizing metastases of insulinoma is challenging. Imaging modalities like CT and MRI show limited results. Somatostatin-receptor (SSTR) imaging (SRS) performs better. However, a subgroup of malignant insulinoma lack SSRT-2 and can, therefore, not be localized using SRS. We propose that in these cases GLP-1R imaging, using the stable GLP-1 analog exendin, could play an important role.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Msc. Marti Boss
#2261 Mechanisms of Main Pancreatic Duct Dilatation in Pancreatic Neuroendocrine Tumors (PanNETs): Radiopathologic Correlation
Introduction: Main pancreatic duct (MPD) dilatation, a frequent observation in cases with adenocarcinoma can also be observed in patients with PanNET.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Jerome Cros
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Louis de Mestier
#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study
Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Prof Rachel Riechelmann
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...